M
Martin F. Sprinzl
Researcher at University of Mainz
Publications - 94
Citations - 2512
Martin F. Sprinzl is an academic researcher from University of Mainz. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 75 publications receiving 2052 citations. Previous affiliations of Martin F. Sprinzl include Technische Universität München & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.
Julie Lucifora,Yuchen Xia,Florian Reisinger,Ke Zhang,Daniela Stadler,Xiaoming Cheng,Martin F. Sprinzl,Herwig Koppensteiner,Zuzanna Makowska,Tassilo Volz,Caroline Remouchamps,Wen Min Chou,Wolfgang E. Thasler,Norbert Hüser,David Durantel,T. Jake Liang,Carsten Münk,Markus H. Heim,Jeffrey L. Browning,Emmanuel Dejardin,Maura Dandri,Michael Schindler,Mathias Heikenwalder,Ulrike Protzer +23 more
TL;DR: It is described how interferon-α can induce specific degradation of the nuclear viral DNA without hepatotoxicity and proposed lymphotoxin-β receptor activation as a therapeutic alternative and the development of new therapeutics that, in combination with existing antivirals, may cure hepatitis B.
Journal ArticleDOI
Transfer of Hepatitis B Virus Genome by Adenovirus Vectors into Cultured Cells and Mice: Crossing the Species Barrier
TL;DR: Adenovirus-mediated genome transfer initiated efficient hepatitis B virus replication in cultured liver cells and in the experimental animals from an extrachromosomal template, which will allow development of small-animal systems of hepatitis Birus infection and will facilitate study of pathogenicity of wild-type and mutant viruses.
Journal ArticleDOI
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Martin F. Sprinzl,Martin F. Sprinzl,Florian Reisinger,Andreas S. Puschnik,Marc Ringelhan,Kerstin Ackermann,Daniel Hartmann,Matthias Schiemann,Arndt Weinmann,Peter R. Galle,Marcus Schuchmann,Helmut Friess,Gerd Otto,Mathias Heikenwalder,Ulrike Protzer +14 more
TL;DR: Sorafenib triggers proinflammatory activity of TAM and subsequently induces antitumor NK cell responses in a cytokine‐ and NF‐κB‐dependent fashion and is relevant for HCC therapy, as sorafenIB is a compound in clinical use that reverts alternative polarization of TAM in HCC.
Journal ArticleDOI
T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
C. Dargel,Michal Bassani-Sternberg,Julia Hasreiter,Fabio Zani,JH Bockmann,Frank Thiele,Felix Bohne,Karin Wisskirchen,Susanne Wilde,Martin F. Sprinzl,Dolores Schendel,Angela M. Krackhardt,Wolfgang Uckert,Dirk Wohlleber,Matthias Schiemann,Kerstin Stemmer,Mathias Heikenwalder,Dirk H. Busch,Gunther Richter,Matthias Mann,Ulrike Protzer +20 more
TL;DR: A GPC3367-specific T-cell receptor is identified that allows T cells to recognize and kill GPC3-positive hepatoma cells and could be used to advance development of adoptive T- cell therapy for HCC.
Journal ArticleDOI
Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients
Christian Labenz,J. S. Baron,Gerrit Toenges,Jörn M. Schattenberg,Michael Nagel,Martin F. Sprinzl,M Nguyen-Tat,Tim Zimmermann,Yvonne Huber,Jens U. Marquardt,Peter R. Galle,MA Wörns +11 more
TL;DR: Data regarding the impact of CHE on health‐related quality of life (HRQoL) and sleep quality are controversial.